Today: 8 June 2026
Browse Category

NASDAQ:MRNA 5 December 2025 - 13 January 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 13.01.2026

WHSP Holdings insiders, led by Robert Millner, bought AU$3.4 million in shares over 12 months with no insider sales; insiders now hold 5.4% of the company. JPMorgan Chase dropped over 3% midday after missing estimates, while Moderna surged 14% on a strong 2025 sales forecast. Arch Capital Group trades near $90.77 as momentum slows, with analysts’ targets averaging $108.31. BofA Securities upgraded Coinbase Global to Buy, setting a $340 target.
13 January 2026
·····
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)

Moderna shares fell 4% to $32.92 Monday after the company raised its 2025 revenue forecast to $1.9 billion and projected operating expenses of up to $5.2 billion. CFO Jamey Mock said U.S. retail vaccination rates dropped 26% in 2025. The company expects about $8.1 billion in year-end cash, including $600 million from a new loan. Investors remain cautious as pandemic demand fades and late-stage vaccine trial results approach.
12 January 2026
···
Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next

Moderna shares fell about 2% to $33.60 early Monday after the company forecast $1.9 billion in 2025 revenue and cut its GAAP operating-expense outlook. CFO James Mock said U.S. retail vaccination rates dropped 26% year-on-year, helping sales hit the low end of forecasts. Moderna expects to end 2025 with about $8.1 billion in cash, including a planned $600 million loan draw. CEO Stéphane Bancel announced a $2 billion annual expense cut for 2025.
12 January 2026
·
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Bayer’s Monsanto filed a lawsuit against Pfizer, BioNTech, and Moderna in Delaware federal court, alleging misuse of mRNA technology patents. Pfizer shares rose 0.9% to $25.67 in early trading after UBS began coverage with a Neutral rating and a $25 price target. Investors are watching for Pfizer’s Q4 and full-year 2025 results on February 3.
7 January 2026
····
S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

The S&P 500 closed at 6,944.82, up 0.62%, while the Dow hit a record. SanDisk surged over 27% and Western Digital gained 17% after Nvidia’s CES appearance. Labor data including JOLTS and payrolls are due this week, with CPI and JPMorgan Chase earnings set for Jan. 13. A Reuters poll shows most strategists expect a 2026 market correction and S&P 500 at 7,490 by year-end.
7 January 2026
·····
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna shares fell 1.4% to $35.15 premarket Wednesday after a 10.9% surge Tuesday, following news it filed for approval of its mRNA flu vaccine in the U.S., Europe, Canada, and Australia. The company reported 26.6% relative efficacy for the vaccine in adults 50 and older. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers Tuesday, alleging mRNA patent infringement.
7 January 2026
··
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

The Dow Jones closed above 49,000 for the first time Tuesday, ending at 49,462.08, up 1%. Chip and healthcare stocks led gains, with Moderna jumping nearly 11% and the PHLX semiconductor index hitting a record. Data-storage shares surged, while Nvidia and AMD slipped after CES presentations. Investors await Wednesday’s JOLTS and Friday’s U.S. jobs report for rate clues.
6 January 2026
······
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

The Dow hit a record high Tuesday, rising 1.02% to 49,476.54 as chip and healthcare shares led gains. SanDisk surged 23% on AI hardware optimism tied to CES, while Johnson Controls fell 7.5% after Nvidia’s chip announcement. Investors monitored U.S. jobs data and Fed signals following gaps caused by last year’s federal shutdown.
6 January 2026
············
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna shares fell 4.73% to $31.20 Friday, closing out a volatile holiday week with no major company news or FDA headlines in the past 48 hours. After-hours trading edged lower near $31.10. Barron’s and MarketBeat flagged the stock’s sharp move and heavy trading volume. Analyst commentary focused on technicals and sector positioning rather than new fundamentals.
28 December 2025
··
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna shares fell about 4.4% to $31.31 in early afternoon trading Tuesday, underperforming a steady broader market near record highs. Trading volume was light, typical for the post-holiday period. No single news event drove the decline, with analysts citing thin liquidity and ongoing uncertainty around U.S. vaccine policy and Moderna’s future pipeline.
26 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna shares fell 7.48% to $32.29 on Dec. 23 after a sharp rally earlier in the week. The drop followed news of up to $54.3 million in CEPI funding for its bird flu vaccine, with a Phase 3 trial set for early 2026. The stock’s volatility contrasted with broader market gains, as investors reacted to recent headlines and year-end trading dynamics.
24 December 2025
··
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna shares rose about 9% to $33.80 after the company secured up to $54.3 million from CEPI for a Phase 3 trial of its H5 bird flu vaccine. The funding follows a canceled U.S. government contract earlier this year. Meanwhile, U.S. regulators are reviewing possible COVID-19 vaccine safety issues, with conflicting reports on potential FDA warnings.
20 December 2025
·
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna shares dropped 7% on December 1 after news that the FDA may tighten vaccine approval standards, following an internal memo linking COVID-19 vaccines to pediatric deaths. The stock rebounded to close at $27.70 on December 5, up 8.7% after a large French study reaffirmed the safety of its vaccine. Moderna’s market cap now stands at $10.8 billion, far below its pandemic peak.
6 December 2025
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
1 2 3

Stock Market Today

  • Nvidia Stock Forecast: Potential to Reach $300 by 2027 Amidst Strong AI-Driven Growth
    June 8, 2026, 5:00 PM EDT. Nvidia (NASDAQ: NVDA) posted a remarkable Q1 FY27 with revenue surging 85% year-on-year to $81.6 billion and free cash flow hitting $48.55 billion. Despite this, shares trade at $205.10, presenting a forward price-to-earnings (P/E) ratio of 26, below the 38x needed to reach $300 by 2027, per Wall Street's consensus target of $298. Nvidia's growth is propelled by AI infrastructure spending, with Q2 revenue guidance at $91 billion and $119 billion in supply commitments. Challenges include geopolitical issues in China and market sensitivity, but analyst sentiment remains 95% bullish. Our model predicts a $255 base case by mid-2027, reflecting 25% upside, while the $300 target requires significant earnings per share growth and multiple expansion. Nvidia remains a key player in AI and data center sectors.

Latest articles

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

IonQ Jumps as Quantum IPO Rush Sets Wall Street Benchmark

8 June 2026
IonQ surged 10.5% to $62.77, outpacing quantum peers after Quantinuum’s $1.68 billion Nasdaq IPO gave investors a new benchmark for trapped-ion quantum stocks; IonQ’s rally follows its May guidance raise and soaring revenue, but losses and a long commercialization timeline remain key risks.
Snap Shares Climb as Debt Markets Send Signal

Snap Drops Again as Wall Street Stays Wary

8 June 2026
Snap plunged 2.1% to $5.64, underperforming a tech rebound, as investors weighed improved cash flow and a recent S&P credit upgrade against ongoing ad-market pressure, cost cuts, and spending on Specs; the stock’s weakness stood out as peers like Pinterest gained, highlighting market doubts about Snap’s ability to sustain growth amid tough competition and uncertain ad budgets.
Dow Drops After Hours, AI Rally Sidesteps Blue Chips

Dow Drops After Hours, AI Rally Sidesteps Blue Chips

8 June 2026
The Dow Jones fell 104.70 points, or 0.21%, to 50,762.08 as tech and chip stocks rebounded sharply, with the Philadelphia SE Semiconductor Index up 6.2% after Friday’s $1 trillion selloff; Apple dropped 1.4% despite its AI event, and investors now await Wednesday’s inflation data and Middle East energy risks as the next key tests for the market’s fragile rebound.
Nasdaq rises as AI names find support after market selloff

Nasdaq rises as AI names find support after market selloff

8 June 2026
Nasdaq surged 1.27% as investors snapped up AI and chip stocks after Friday’s rout, with the Philadelphia Semiconductor Index jumping 6.2%; Citigroup hiked its S&P 500 year-end target to 8,100 on AI demand, but Goldman Sachs warned strong jobs data makes a Fed rate hike more plausible, posing risks to growth stocks if inflation surprises.
Go toTop